BioMarin Pharmaceutical Inc. said an experimental treatment for Morquio A Syndrome, a rare genetic disease, succeeded in a clinical trial. The disease causes systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance.
BioMarin Pharmaceutical drug succeeds in clinical trial
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week